A review of the importance of immune responses in luminal B breast cancer

References

• IARC. In Stewart BW, Wild CP, eds. World Cancer Report 2014. Lyon, France: World Health Organisation 2014:16-27.
   Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800; PMID:19228622; http://dx.doi.org/10.1056/NEJMra0801289
   PubMed Web of Science ®Google Scholar
• Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harbor Perspectives in Biol 2011; 3:1-17; http://dx.doi.org/10.1101/cshperspect.a003293
   PubMed Web of Science ®Google Scholar
• Fisher ER, Fisher B, Sass R, Wickerham L. Pathologic findings from the national surgical adjuvant breast project (Protocol No. 4). XI. Bilateral breast cancer. Cancer 1984; 54:3002-11; PMID:6498774; http://dx.doi.org/10.1002/1097-0142(19841215)54:12%3c3002::AID-CNCR2820541231%3e3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96:1504-13; PMID:17453008; http://dx.doi.org/10.1038/sj.bjc.6603756
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012; 21:1848-55; PMID:22989461; http://dx.doi.org/10.1158/1055-9965.EPI-12-0474
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013; 31:3083-90; PMID:23897954; http://dx.doi.org/10.1200/JCO.2012.46.1574
   PubMed Web of Science ®Google Scholar
• Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 2001; 166:5557-66; PMID:11313395; http://dx.doi.org/10.4049/jimmunol.166.9.5557
   PubMed Web of Science ®Google Scholar
• Jackaman C, Nelson DJ. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?. Exp Gerontol 2014; 54:53-7; PMID:24291067; http://dx.doi.org/10.1016/j.exger.2013.11.009
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Curigliano G. Immunotherapy of Breast Cancer. Prog Tumor Res 2015; 42:30-43; PMID:26377084; http://dx.doi.org/10.1159/000437183
   PubMed Web of Science ®Google Scholar
• Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W et al. Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer Immunol Res 2016; 4:600-10; PMID:27197066; http://dx.doi.org/10.1158/2326-6066.CIR-15-0149
   PubMed Web of Science ®Google Scholar
• Casbas-Hernandez P, Sun X, Roman-Perez E, D'Arcy M, Sandhu R, Hishida A, McNaughton KK, Yang XR, Makowski L, Sherman ME et al. Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev 2015; 24:406-14; PMID:25465802; http://dx.doi.org/10.1158/1055-9965.EPI-14-0934
   PubMed Web of Science ®Google Scholar
• Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verrièle V et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: Importance of immune response. Breast Cancer Res 2015; 17:43; PMID:25887482; http://dx.doi.org/10.1186/s13058-015-0550-y
   PubMed Web of Science ®Google Scholar
• Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy 2016; 12:864-75; PMID:26979828; http://dx.doi.org/10.1080/15548627.2016.1154244
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review. JAMA Oncol 2016; 2:1354-60; PMID:27355489; http://dx.doi.org/10.1001/jamaoncol.2016.1061
   PubMed Web of Science ®Google Scholar
• Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14:364-75; PMID:19145485; http://dx.doi.org/10.1007/s10495-008-0303-9
   PubMed Web of Science ®Google Scholar
• Haynes NM, van der Most RG, Lake RA, Smyth MJ. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 2008; 20:545-57; PMID:18573339; http://dx.doi.org/10.1016/j.coi.2008.05.008
   PubMed Web of Science ®Google Scholar
• McDonnell AM, Joost Lesterhuis W, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW. Restoration of defective cross-presentation in tumors by gemcitabine. Oncoimmunology 2015; 4:e1005501; PMID:26155402; http://dx.doi.org/10.1080/2162402X.2015.1005501
   PubMed Web of Science ®Google Scholar
• Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68:4026-30; PMID:18519658; http://dx.doi.org/10.1158/0008-5472.CAN-08-0427
   PubMed Web of Science ®Google Scholar
• Kroemer G, Piacentini M. Dying to survive - apoptosis, necroptosis, autophagy as supreme experiments of nature. Int J Dev Biol 2015; 59:5-9; PMID:26374520; http://dx.doi.org/10.1387/ijdb.150167mp
   PubMed Web of Science ®Google Scholar
• Sharma A, Ramanjaneyulu A, Ray R, Rajeswari MR. Involvement of high mobility group B proteins in cisplatin-induced cytotoxicity in squamous cell carcinoma of skin. DNA Cell Biol 2009; 28:311-8; PMID:19435426; http://dx.doi.org/10.1089/dna.2009.0851
   PubMed Web of Science ®Google Scholar
• Jackaman C, Majewski D, Fox SA, Nowak AK, Nelson DJ. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo. Cancer Immunol Immunother 2012; 61:2343-56; PMID:22714286; http://dx.doi.org/10.1007/s00262-012-1307-4
   PubMed Web of Science ®Google Scholar
• Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3:e27884; PMID:24790795; http://dx.doi.org/10.4161/onci.27884
   PubMed Web of Science ®Google Scholar
• van Rooijen JM, Stutvoet TS, Schroder CP, de Vries EG. Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacol Ther 2015; 156:90-101; PMID:26388292; http://dx.doi.org/10.1016/j.pharmthera.2015.09.003
   PubMed Web of Science ®Google Scholar
• Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The influence of host factors on the prognosis of breast cancer: Stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets 2015; 15:652-64; PMID:26452382; http://dx.doi.org/10.2174/156800961508151001101209
   PubMed Web of Science ®Google Scholar
• Maley CC, Koelble K, Natrajan R, Aktipis A, Yuan Y. An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res 2015; 17:131; PMID:26395345; http://dx.doi.org/10.1186/s13058-015-0638-4
   PubMed Web of Science ®Google Scholar
• Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R, Jr., Miller LD. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med 2014; 6:80; PMID:25419236; http://dx.doi.org/10.1186/s13073-014-0080-8
   PubMed Web of Science ®Google Scholar
• Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71:4809-20; PMID:21646474; http://dx.doi.org/10.1158/0008-5472.CAN-11-0753
   PubMed Web of Science ®Google Scholar
• Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol 2003; 171:5051-63; PMID:14607902; http://dx.doi.org/10.4049/jimmunol.171.10.5051
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Seminars Cancer Biol 2006; 16:115-23; http://dx.doi.org/10.1016/j.semcancer.2005.11.005
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 2015; 33:101-11; PMID:25728990; http://dx.doi.org/10.1016/j.coi.2015.02.003
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006; 42:717-27; PMID:16520032; http://dx.doi.org/10.1016/j.ejca.2006.01.003
   PubMed Web of Science ®Google Scholar
• Jackaman C, Yeoh TL, Acuil ML, Gardner JK, Nelson DJ. Murine mesothelioma induces locally-proliferating IL-10(+)TNF-alpha(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy. Oncoimmunology 2016; 5:e1173299; PMID:27471652; http://dx.doi.org/10.1080/2162402X.2016.1173299
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-94; http://dx.doi.org/10.1146/annurev.immunol.19.1.565
   PubMed Web of Science ®Google Scholar
• Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. P & T 2012; 37:503-30.
   PubMedGoogle Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
   PubMed Web of Science ®Google Scholar
• Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q, Qu X. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 2010; 10:728-36; PMID:20578982; http://dx.doi.org/10.2174/156800910793605811
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862
   PubMed Web of Science ®Google Scholar
• Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24:743-50; PMID:24782321; http://dx.doi.org/10.1101/gr.165985.113
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34:1510-7; PMID:26951310; http://dx.doi.org/10.1200/JCO.2015.64.0391
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Cha E, Wallin J, Kowanetz M. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol 2015; 42:484-7; PMID:25965367; http://dx.doi.org/10.1053/j.seminoncol.2015.02.002
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; http://dx.doi.org/10.1038/nature13904
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol 2015; 42:474-83; PMID:25965366; http://dx.doi.org/10.1053/j.seminoncol.2015.02.007
   PubMed Web of Science ®Google Scholar
• Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arłukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E et al. Immune response in breast cancer brain metastases and their microenvironment: The role of the PD-1/PD-L axis. Breast Cancer Res 2016; 18:43; PMID:27117582; http://dx.doi.org/10.1186/s13058-016-0702-8
   PubMed Web of Science ®Google Scholar
• Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014; 63:395-406; PMID:24514954; http://dx.doi.org/10.1007/s00262-014-1519-x
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139:667-76; PMID:23756627; http://dx.doi.org/10.1007/s10549-013-2581-3
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008; 8:57; PMID:18294387; http://dx.doi.org/10.1186/1471-2407-8-57
   PubMed Web of Science ®Google Scholar
• Zawlik I, Gablo N, Szymanska B, Pawlowska Z, Chudobinski C, Chalubinska-Fendler J, Morawiec Z, Zielinska-Blizniewska H, Morawiec-Sztandera A, Kolacinska A. Immune checkpoints in aggressive breast cancer subtypes. Neoplasma 2016; 63:768-73; PMID:27468881; http://dx.doi.org/10.4149/neo_2016_514
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165:35-44; PMID:26997480; http://dx.doi.org/10.1016/j.cell.2016.02.065
   PubMed Web of Science ®Google Scholar
• Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, Benko E, Kovacs C, Ostrowski MA. Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol 2012; 188:3745-56; PMID:22422881; http://dx.doi.org/10.4049/jimmunol.1102609
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245-52; PMID:16286920; http://dx.doi.org/10.1038/ni1271
   PubMed Web of Science ®Google Scholar
• Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 2010; 185:1383-92; PMID:20574007; http://dx.doi.org/10.4049/jimmunol.0903275
   PubMed Web of Science ®Google Scholar
• Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21:1258-65; PMID:21187321; http://dx.doi.org/10.1093/glycob/cwq214
   PubMed Web of Science ®Google Scholar
• Heusschen R, Griffioen AW, Thijssen VL. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta 2013; 1836:177-85; PMID:23648450; http://dx.doi.org/10.1016/j.bbcan.2013.04.006
   PubMed Web of Science ®Google Scholar
• Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009; 39:2492-501; PMID:19676072; http://dx.doi.org/10.1002/eji.200939274
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Thijssen VL. Galectins in tumor angiogenesis. Ann Transl Med 2014; 2:90; PMID:25405165; http://dx.doi.org/10.3978/j.issn.2305-5839.2014.09.01
   PubMedGoogle Scholar
• Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, Zhu C, Hirashima M, Anderson AC, Kuchroo VK. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 2014; 41:270-82; PMID:25065622; http://dx.doi.org/10.1016/j.immuni.2014.06.011
   PubMed Web of Science ®Google Scholar
• Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget 2016; 7:18183-203; PMID:26933916; http://dx.doi.org/10.18632/oncotarget.7784
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096
   PubMed Web of Science ®Google Scholar
• Kim OH, Kang GH, Noh H, Cha JY, Lee HJ, Yoon JH, Mamura M, Nam JS, Lee DH, Kim YA et al. Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes. Mol Cells 2013; 36:432-8; PMID:24158612; http://dx.doi.org/10.1007/s10059-013-0194-7
   PubMed Web of Science ®Google Scholar
• Sica A, Allavena P, Mantovani A. Cancer related inflammation: The macrophage connection. Cancer Lett 2008; 267:204-15; PMID:18448242; http://dx.doi.org/10.1016/j.canlet.2008.03.028
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83; PMID:17617589; http://dx.doi.org/10.4049/jimmunol.179.2.977
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393-8; PMID:12917485; http://dx.doi.org/10.1073/pnas.1732912100
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer immun 2010; 10:9; PMID:20957980
   PubMedGoogle Scholar
• Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 2004; 136:463-71; PMID:15147348; http://dx.doi.org/10.1111/j.1365-2249.2004.02478.x
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792
   PubMed Web of Science ®Google Scholar
• Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 2015; 7:1120-34; PMID:25959051; http://dx.doi.org/10.1039/C5IB00040H
   PubMed Web of Science ®Google Scholar
• Carrio R, Koru-Sengul T, Miao F, Gluck S, Lopez O, Selman Y et al. Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep 2013; 29:141-8; PMID:23076599; http://dx.doi.org/10.3892/or.2012.2088
   PubMed Web of Science ®Google Scholar
• Stoll G, Zitvogel L, Kroemer G. Immune infiltrate in cancer. Aging 2015; 7:358-9; PMID:26143478; http://dx.doi.org/10.18632/aging.100770
   PubMedGoogle Scholar
• Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs working group 2014. Ann Oncol 2015; 26:259-71; PMID:25214542; http://dx.doi.org/10.1093/annonc/mdu450
   PubMed Web of Science ®Google Scholar
• Harvey J, Thomas C, Wood B, Hardie M, Dessauvagie B, Combrinck M, Frost FA, Sterrett G. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting. Pathology 2015; 47:13-20; PMID:25474507; http://dx.doi.org/10.1097/PAT.0000000000000192
   PubMed Web of Science ®Google Scholar
• Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat 2012; 132:895-915; PMID:22048814; http://dx.doi.org/10.1007/s10549-011-1837-z
   PubMed Web of Science ®Google Scholar
• Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 2013; 16:32-9; PMID:23593079; http://dx.doi.org/10.4048/jbc.2013.16.1.32
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar